<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30132256</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1543-706X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>54</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>In vitro cellular &amp; developmental biology. Animal</Title>                <ISOAbbreviation>In Vitro Cell. Dev. Biol. Anim.</ISOAbbreviation>            </Journal>            <ArticleTitle>Is miR-144 an effective inhibitor of PTEN mRNA: a controversy in breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>621-628</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11626-018-0282-2</ELocationID>            <Abstract>                <AbstractText>Breast cancer is the first common cancer among women worldwide. One of the major signaling pathways playing a role in the onset and progression of this disease is PI3K/Akt/mTOR, which can be inhibited by PTEN. miRNAs are small non-coding molecules that regulate the expression of their targets by inhibition or suppression, and thus, their dysregulated expression results in the development of cancer. Using various software applications predicting miRNAs and evaluating GEO microarray data, miR-144 was selected as an inhibitor of PTEN. The expression of miR-144 and PTEN was evaluated in 18 triple negative breast cancer (TNBC) clinical samples and cell lines including 4T1, MDA-MB-231, MDA-MB-468, SK-BR-3, and MCF-7 in comparison with normal cells. PTEN and miR-144 expression analysis revealed their elevated expression in MCF-7 cells. MDA-MB-468, SK-BR-3, and MDA-MB-231 cells showed decreased levels of PTEN and increased levels of miR-144. In contrast, 4T1 cells had an increased expression of PTEN and decreased expression of miR-144. In clinical samples, miR-144 was up-regulated in 22% of the cases and PTEN was down-regulated in 78% of the cases. The results showed that the expression of PTEN and miR-144 was inversely correlated in metastatic breast cancer cell lines. However, in TNBC clinical samples, there was no correlation between the expression of miR-144 and PTEN. Literature shows that there are other influencing factors affecting the expression of miRNAs. Therefore, care should be taken in interpreting the results of gene expression studies and its relation with cancer diagnosis/prognosis.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kia</LastName>                    <ForeName>Vahid</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Biotechnology and nanotechnology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sharif Beigli</LastName>                    <ForeName>Maryam</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Islamic Azad University, East Tehran branch Campus, Tehran, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hosseini</LastName>                    <ForeName>Vahedeh</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Koochaki</LastName>                    <ForeName>Ameneh</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paryan</LastName>                    <ForeName>Mahdi</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Research and Development, Production and Research Complex, Pasteur Institute of Iran, P.O. Box: 3159915111, Tehran, Iran. m_paryan@pasteur.ac.ir.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mohammadi-Yeganeh</LastName>                    <ForeName>Samira</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. s.mohammadiyeganeh@sbmu.ac.ir.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. s.mohammadiyeganeh@sbmu.ac.ir.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>5639</GrantID>                    <Agency>Shahid Beheshti University of Medical Sciences</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>21</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>In Vitro Cell Dev Biol Anim</MedlineTA>            <NlmUniqueID>9418515</NlmUniqueID>            <ISSNLinking>1071-2690</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Biol Rep. 2013 May;40(5):3665-74</RefSource>                <PMID Version="1">23307300</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Oncol. 2013 Sep 17;3:240</RefSource>                <PMID Version="1">24062990</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World J Clin Oncol. 2014 May 10;5(2):48-60</RefSource>                <PMID Version="1">24829851</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2005 Jan 14;120(1):15-20</RefSource>                <PMID Version="1">15652477</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 1997 Oct 1;57(19):4187-90</RefSource>                <PMID Version="1">9331072</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pathol. 2004 Sep;204(1):93-100</RefSource>                <PMID Version="1">15307142</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2012 May 2;307(17):1827-37</RefSource>                <PMID Version="1">22550197</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 1999 Nov 3;91(21):1820-8</RefSource>                <PMID Version="1">10547389</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2007 Oct 11;449(7163):682-8</RefSource>                <PMID Version="1">17898713</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocrinology. 2015 Jul;156(7):2429-39</RefSource>                <PMID Version="1">25919186</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer Res Clin Oncol. 2010 Sep;136(9):1303-11</RefSource>                <PMID Version="1">20300775</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 Aug 14;6(23):19759-79</RefSource>                <PMID Version="1">26078353</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 1997 Nov 15;57(22):4997-5000</RefSource>                <PMID Version="1">9371490</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genome Biol. 2010;11(8):R90</RefSource>                <PMID Version="1">20799968</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nucleic Acids Res. 2015 Jan;43(Database issue):D153-9</RefSource>                <PMID Version="1">25416803</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nucleic Acids Res. 2016 Jan 4;44(D1):D239-47</RefSource>                <PMID Version="1">26590260</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Med. 2014 Dec 03;12:224</RefSource>                <PMID Version="1">25465851</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62</RefSource>                <PMID Version="1">24114568</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>FEBS J. 2013 Sep;280(18):4531-8</RefSource>                <PMID Version="1">23815091</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomed Pharmacother. 2017 Oct;94:341-353</RefSource>                <PMID Version="1">28772212</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Annu Rev Pharmacol Toxicol. 2011;51:25-43</RefSource>                <PMID Version="1">20809797</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Carcinogenesis. 2016 May;37(5):461-70</RefSource>                <PMID Version="1">26785733</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Carcinogenesis. 2013 Feb;34(2):454-63</RefSource>                <PMID Version="1">23125220</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2005 Aug 15;65(16):7065-70</RefSource>                <PMID Version="1">16103053</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2010 Oct 25;5(10):e13599</RefSource>                <PMID Version="1">21049042</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Res. 2015 Jul;35(7):3969-77</RefSource>                <PMID Version="1">26124344</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Methods Mol Biol. 2014;1182:289-305</RefSource>                <PMID Version="1">25055920</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Endocrinol. 2011 Apr;7(4):208-18</RefSource>                <PMID Version="1">21200394</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2010 Jun 24;465(7301):1033-8</RefSource>                <PMID Version="1">20577206</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">PTEN</Keyword>            <Keyword MajorTopicYN="N">Triple negative breast cancer</Keyword>            <Keyword MajorTopicYN="N">miR-144</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30132256</ArticleId>            <ArticleId IdType="doi">10.1007/s11626-018-0282-2</ArticleId>            <ArticleId IdType="pii">10.1007/s11626-018-0282-2</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>